(Q36071504)

English

Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI.

scientific article

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI. (English)

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

0 references

Clostridium difficile

0 references

1 reference

ChEBI release 2020-05-28

author name string

Thomas J Louie

1

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Kris Cannon

2

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Brendan Byrne

3

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Judy Emery

4

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Linda Ward

5

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Melissa Eyben

6

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Walter Krulicki

7

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

language of work or name

0 references

publication date

1 August 2012

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Clinical Infectious Diseases

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

55 Suppl 2

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

S132-42

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Fidaxomicin versus vancomycin for Clostridium difficile infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3388020

2 October 2017

Comparative metagenomic study of alterations to the intestinal microbiota and risk of nosocomial Clostridum difficile-associated disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3388020

2 October 2017

Fecal bacteriotherapy for recurrent Clostridium difficile infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3388020

2 October 2017

Clostridium difficile--more difficult than ever

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3388020

2 October 2017

Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3388020

2 October 2017

OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3388020

2 October 2017

Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3388020

2 October 2017

Decreased diversity of the fecal Microbiome in recurrent Clostridium difficile-associated diarrhea

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3388020

2 October 2017

Outcomes of Clostridium difficile-associated disease treated with metronidazole or vancomycin before and after the emergence of NAP1/027.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3388020

2 October 2017

A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3388020

2 October 2017

Treatment of Clostridium difficile-associated disease: old therapies and new strategies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3388020

2 October 2017

Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3388020

2 October 2017

Diversity of the human intestinal microbial flora

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3388020

2 October 2017

In vitro activities of OPT-80 and comparator drugs against intestinal bacteria

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3388020

2 October 2017

Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3388020

2 October 2017

Characterization of bacterial communities in feces from healthy elderly volunteers and hospitalized elderly patients by using real-time PCR and effects of antibiotic treatment on the fecal microbiota

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3388020

2 October 2017

Development of 16S rRNA-gene-targeted group-specific primers for the detection and identification of predominant bacteria in human feces

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3388020

2 October 2017

Identification of nonpoint sources of fecal pollution in coastal waters by using host-specific 16S ribosomal DNA genetic markers from fecal anaerobes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3388020

2 October 2017

Colonization resistance of the digestive tract of mice during systemic antibiotic treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3388020

2 October 2017

In vitro and in vivo evaluation of tiacumicins B and C against Clostridium difficile

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3388020

2 October 2017

A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3388020

23 September 2018

Effect of antibiotic therapy on human fecal microbiota and the relation to the development of Clostridium difficile

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3388020

23 September 2018

Development of an extensive set of 16S rDNA-targeted primers for quantification of pathogenic and indigenous bacteria in faecal samples by real-time PCR.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3388020

23 September 2018

Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3388020

23 September 2018

Ten Years of Prospective Clostridium difficile-Associated Disease Surveillance and Treatment at the Minneapolis VA Medical Center, 1982–1991

1 reference

https://pubmed.ncbi.nlm.nih.gov/22752862

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea

1 reference

https://pubmed.ncbi.nlm.nih.gov/22752862

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quantification of Bifidobacterium spp. and Lactobacillus spp. in rat fecal samples by real-time PCR

1 reference

https://pubmed.ncbi.nlm.nih.gov/22752862

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/22752862

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Determination of bacterial load by real-time PCR using a broad-range (universal) probe and primers set

1 reference

https://pubmed.ncbi.nlm.nih.gov/22752862

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1093/CID/CIS338

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36071504&oldid=1996604795"